Labous (Chlormadinone Acetate, Ethinylestradiol)

Labous, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy and manage menstrual disorders.

• Pregnancy prevention: prevents ovulation and creates an unfavorable uterine environment to reduce the chance of fertilization.
• Menstrual cycle regulation: provides predictable withdrawal bleeding and stabilizes cycle length.
• Acne management: reduces androgenic activity, leading to improvement of acne symptoms in some women.

• Chlormadinone acetate is a progestogenic steroid that binds to progesterone receptors, suppressing the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), thereby inhibiting ovulation. Ethinylestradiol provides estrogenic activity, stabilizing the endometrium and enhancing negative feedback on gonadotropin release. Together they alter cervical mucus and endometrial development, creating conditions unfavorable for fertilization and implantation.

Labous may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring early in treatment.
• Breast tenderness: discomfort or swelling of the breasts.
• Headache: mild to moderate headaches.
• Spotting or breakthrough bleeding: irregular vaginal bleeding.
• Weight gain: mild increase in body weight.
• Mood changes: irritability or mood swings.

Serious or Rare Side Effects

• Thromboembolic events: blood clots in veins or arteries.
• Hypertension: significant increase in blood pressure.
• Liver dysfunction: jaundice or abnormal liver enzymes.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Visual disturbances: sudden vision changes or loss.
• Gallbladder disease: inflammation or stones.

Before prescribing Labous, clinicians should evaluate several safety considerations.

• Cardiovascular risk assessment: review history of thrombosis, stroke, or myocardial infarction.
• Smoking status: avoid use in women over 35 who smoke.
• Liver function evaluation: assess hepatic disease before initiating therapy.
• Pregnancy contraindication: discontinue if pregnancy is confirmed or suspected.
• Breastfeeding caution: consider alternative contraception for nursing mothers.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Labous can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive effectiveness.
• Antifungal agents (e.g., ketoconazole, itraconazole): can increase hormone levels, raising side‑effect risk.
• HIV protease inhibitors (e.g., ritonavir): may alter hormone metabolism.
• St. John’s Wort: decreases plasma concentrations, compromising efficacy.
• Certain antibiotics (e.g., griseofulvin): may reduce contraceptive reliability.

Moderate Interactions (Monitor Closely)

• Anticonvulsants (e.g., phenytoin, phenobarbital): may modestly decrease effectiveness.
• Selective serotonin reuptake inhibitors (SSRIs): monitor for mood changes.
• Diuretics (e.g., thiazides): may affect fluid balance and blood pressure.
• Antihypertensives (e.g., ACE inhibitors): observe blood pressure control.
• Herbal supplements (e.g., ginseng): possible interaction with hormone metabolism.